Four recent first-line clinical trials leveraging immune-oncology agents demonstrated an overall survival (OS) benefit relative to sunitinib. We aimed to provide formal comparisons among immune-oncology combinations in term of OS, progression-free survival (PFS), objective response rates (ORR) and treatment-related adverse events (AEs).

X